ENDRA Life Sciences (NDRA) Total Liabilities (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported Total Liabilities for 11 consecutive years, with $1.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities rose 22.33% year-over-year to $1.6 million in Q2 2026; TTM through Jun 2026 was $1.6 million, a 22.33% increase from a year earlier, with the FY2025 full-year figure at $1.6 million, down 15.77% from the prior year.
• Total Liabilities was $1.6 million for Q2 2026 at ENDRA Life Sciences, down from $1.7 million in the prior quarter.
• Over five years, Total Liabilities peaked at $2.4 million in Q3 2023 and troughed at $1.1 million in Q4 2023.
• A 5-year average of $1.8 million and a median of $1.8 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities jumped 78.48% in 2022 and tumbled 47.08% in 2023, its largest moves.
• Over 5 years, Total Liabilities stood at $2.1 million in 2022, then sank by 47.08% to $1.1 million in 2023, then jumped by 72.76% to $1.9 million in 2024, then retreated by 15.77% to $1.6 million in 2025, then increased by 2.44% to $1.6 million in 2026.
• The last three Total Liabilities figures came in at $1.6 million (Q2 2026), $1.7 million (Q1 2026), and $1.6 million (Q4 2025), per Business Quant data.